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Correspondence Mechanical Valve Thrombosis With DabigatranTo the Editor: Dabigatran etexilate is an oral direct thrombin
inhibitor that has recently been approved for anticoagulation of
nonvalvular atrial fibrillation (AF). While this medication pos-
sesses a number of characteristics that make it an attractive
alternative to warfarin, its use for other indications currently
remains untested. We report 2 cases of patients with mechanical
heart valves who were switched from warfarin to dabigatran
leading to thrombosis of their prosthetic valves.
Case 1. A 51-year-old woman presented with a 4-week history of
progressive exertional dyspnea. She underwent a mechanical aortic
valve replacement 8 years prior. Two months earlier, her general
practitioner switched her from warfarin to dabigatran (150 mg,
twice daily) for mechanical valve anticoagulation. This patient did
not have AF, had been compliant with warfarin therapy with no
adverse events, and had normal renal function.
She had coarse crackles bilaterally and a 4/6 systolic murmur in
the aortic area. An echocardiogram revealed severe prosthetic
aortic valve stenosis and severe left ventricular dysfunction with a
probable mass on the prosthesis. The patient was transferred to our
institution in cardiogenic shock and taken emergently to the
operating room. Immediately prior to the operation, the activated
partial thromboplastin time (aPTT) was 27 s. The patient expe-
rienced a cardiac arrest in the operating room and was placed on
Figure 1 Intraoperative Transesophageal Echocardiographic Im
Echocardiogram demonstrating thrombus on the mechanical aortic valve in the (A)cardiopulmonary bypass via the femoral vessels. A transesophageal
echocardiogram confirmed multiple masses on the prosthetic aortic
valve (Fig. 1). Surgical exploration revealed extensive thrombi on
the valve without pannus formation (Fig. 2). The valve was
replaced with a mechanical prosthesis without complication. Di-
alysis was performed while on cardiopulmonary bypass in an
attempt to reduce circulating levels of dabigatran. Despite this the
patient experienced extensive coagulopathy. Her subsequent post-
operative course was uneventful with complete end-organ recovery.
Case 2. A 59-year-old female with a prior mechanical mitral valve
replacement presented for routine follow-up. Since her valve
replacement for rheumatic mitral disease in 2007, the patient had
been treated with warfarin without complication. The patient’s
family physician switched her to dabigatran (150 mg, twice daily)
3 months earlier. She was reportedly compliant with her medica-
tion. The patient was in sinus rhythm and had normal renal
function. She reported progressive dyspnea over the past 2 months.
Transesophageal echocardiogram revealed elevated transprosthetic
gradients, an immobile anterior leaflet, and a large thrombus on
the atrial aspect of the valve. The aPTT was 54 s. Dabigatran was
stopped and 3 days later, the patient was taken to the operating
room. Large amounts of thrombus were found on the mitral valve.
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October 23, 2012:1710–4A mitral valve replacement and tricuspid valve repair were per-
formed. The patient had an uneventful recovery.
Discussion. Thrombosis of a mechanical valve is a potentially
atal complication. With warfarin anticoagulation, the incidence of
alve thrombosis is low (1). In both presented cases, patients were
anticoagulated with warfarin and had never experienced throm-
botic or bleeding events. One month after being switched from
warfarin to dabigatran both patients became symptomatic and
were subsequently diagnosed with thrombosis. While a causal link
is not certain, the temporal association is highly suggestive.
Dabigatran is one of several novel oral anticoagulants evaluated
as a substitute for warfarin. Regulatory approval was based on the
pivotal RE-L-Y (Randomized Evaluation of Long-Term Antico-
agulation Therapy) trial, which compared dabigatran to warfarin
for the treatment of nonvalvular AF (2). This study demonstrated
equivalent freedom from thrombotic events with fewer hemor-
rhagic events for low-dose dabigatran (110 mg, twice daily) and
superior freedom from thrombotic events with equivalent bleeding
with higher dose dabigatran (150 mg, twice daily). Additional
advantages of dabigatran include stable dosing, no requirement for
monitoring, and fewer interactions.
In vitro and animal studies suggest that Dabigatran for mechan-
ical valve anticoagulation may be a potential therapeutic avenue
(3,4). Recently, enoxaparin was compared to dabigatran for anti-
coagulation of mechanical aortic valves. Dabigatran was found to
reduce thrombus burden with a dose of 20 mg/kg twice daily,
corresponding to an aPTT of 2 to 2.5 times normal in the porcine
model. This question is now being addressed with a phase II
clinical trial, RE-ALIGN (NCT01452347), which utilizes doses
ranging from 150 to 330 mg twice daily, adjusted based on renal
function and results of the Hemoclot assay.
The failure of 1 patient to achieve adequate anticoagulation
Figure 2 Thrombosed Aortic Valve Prosthesis
Surgical photograph demonstrating the intraoperative appearance of the pros-
thetic aortic valve. Significant thrombus was observed on both the ventricular
and aortic sides of the prosthesis.despite a “highdose” and that a second experienced valve throm-bosis despite therapeutic aPTT levels highlights the importance of
medication testing for a specific indication. Furthermore, AF may
represent a lesser thrombotic risk than a mechanical prosthesis,
particularly mitral. While there is a wealth of data and clinical
experience on dosing and therapeutic response to warfarin in this
context, these data are unavailable for dabigatran.
Off-label use of novel drugs can jeopardize potential future
applications in new disease contexts and should be avoided until
data from well-designed clinical studies is available. Novel oral
anticoagulants hold tremendous promise for mechanical valve
anticoagulation. However, there is a need for dose-finding studies
and clinical trials to demonstrate safety and efficacy in this setting.
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Letters to the Editor
18F-Fluoride Imaging
or Atherosclerosis
We read with great interest the article on coronary artery calcifi-
cation by Dweck et al. (1) recently published in the Journal.
Although the authors claimed that this communication was the
first on this topic in the literature, we would direct the readership
to our original article, “Detection and global quantification of
cardiovascular molecular calcification by fluoro18-fluoride positron
emission tomography/computed tomography—a novel concept”
(2) and accompanying editorial, “Assessing global cardiovascular
